Live Feeds
● LIVE Updated 1d ago · 15 sources tracked

AbbVie sharpens immunology focus with $10.9 billion Apogee deal

AbbVie is buying Waltham-based Apogee Therapeutics to expand its immunology and inflammatory disease pipeline. This $10.9 billion deal is the company's largest buyout in over five years. The acquisition provides AbbVie with a late-phase eczema drug candidate.

RSS Source map (15)

What changed

AbbVie announced the $10.9 billion acquisition of Apogee Therapeutics.

Live updates

  1. AbbVie acquires Apogee Therapeutics for $10.9 billion

    AbbVie is buying Waltham-based Apogee Therapeutics to expand its immunology and inflammatory disease pipeline. This $10.9 billion deal is the company's largest buyout in over five years. The acquisition provides AbbVie with a late-phase eczema drug candidate.

    What's confirmed:

    • AbbVie is buying Apogee Therapeutics for $10.9 billion.
    • The deal is the largest buyout for AbbVie in more than five years.
    • Apogee Therapeutics is a biotech company based in Waltham.
    • The acquisition targets long-acting autoimmune drugs and treatments for inflammatory diseases.

    Still unconfirmed:

    • The deal includes the lead drug zumilokibart.
    • The late-phase eczema drug candidate could threaten Eli Lilly, Regeneron, and Sanofi.
    confidence 100%